Shoulder Innovations (NYSE:SI) Issues Earnings Results

Shoulder Innovations (NYSE:SI) released its quarterly earnings data on Wednesday. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.03, FiscalAI reports. Shoulder Innovations had a negative net margin of 81.78% and a negative return on equity of 42.98%. The firm had revenue of $16.71 million during the quarter.

Here are the key takeaways from Shoulder Innovations’ conference call:

• First-quarter revenue beat expectations, with net revenue of $16.7 million up 65% year over year and 16% sequentially, while gross margin improved to 77.7%.
• The company raised full-year 2026 revenue guidance to $65 million-$68 million, up from $62 million-$65 million, reflecting confidence in new surgeon adoption, higher utilization, and product launches.
• Commercial momentum remained strong as total implant volume rose 51% year over year, with new customers entering the funnel faster and existing core surgeons increasing usage.
• The company advanced its product pipeline, including full commercial launch of the i135RFX humeral stem, limited user release of the N22 Glenosphere, and progress on its robotic platform with a 510(k) submission targeted for 2027.
• Operating expenses increased, with SG&A and R&D both higher year over year, but management said cash burn should decline meaningfully from Q2 onward and reiterated confidence in reaching cash flow breakeven over time.

Shoulder Innovations Price Performance

SI stock traded up $0.19 during midday trading on Friday, reaching $15.78. The company had a trading volume of 260,642 shares, compared to its average volume of 77,864. The company has a market capitalization of $327.10 million and a price-to-earnings ratio of -0.09. The stock has a 50 day moving average price of $14.07 and a 200-day moving average price of $14.01. Shoulder Innovations has a 1-year low of $10.92 and a 1-year high of $17.94. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.07 and a quick ratio of 9.55.

Insider Transactions at Shoulder Innovations

In related news, CEO Robert Joseph Ball purchased 2,200 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average price of $15.18 per share, with a total value of $33,396.00. Following the completion of the purchase, the chief executive officer directly owned 278,866 shares in the company, valued at $4,233,185.88. This trade represents a 0.80% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jeffrey S. Points purchased 2,000 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $15.00 per share, with a total value of $30,000.00. Following the purchase, the chief financial officer owned 70,785 shares of the company’s stock, valued at $1,061,775. This represents a 2.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 5,200 shares of company stock valued at $78,236. 29.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Shoulder Innovations in the third quarter valued at about $28,000. Rhumbline Advisers acquired a new position in Shoulder Innovations in the third quarter valued at about $54,000. Wells Fargo & Company MN raised its stake in Shoulder Innovations by 66.3% during the fourth quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock worth $75,000 after acquiring an additional 2,094 shares in the last quarter. Board of Trustees of The Leland Stanford Junior University acquired a new position in Shoulder Innovations during the third quarter worth about $170,000. Finally, Renaissance Technologies LLC acquired a new position in Shoulder Innovations during the fourth quarter worth about $176,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on SI shares. BTIG Research lifted their target price on Shoulder Innovations from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Piper Sandler reissued an “overweight” rating and set a $19.00 target price (up from $18.00) on shares of Shoulder Innovations in a report on Friday, May 8th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $21.00.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.